Porton Pharma Solutions Ltd.

SZSE:300363 Stock Report

Market Cap: CN¥8.3b

Porton Pharma Solutions Future Growth

Future criteria checks 5/6

Porton Pharma Solutions is forecast to grow earnings and revenue by 123.9% and 20.6% per annum respectively. EPS is expected to grow by 124.1% per annum. Return on equity is forecast to be 5.3% in 3 years.

Key information

123.9%

Earnings growth rate

124.1%

EPS growth rate

Pharmaceuticals earnings growth19.0%
Revenue growth rate20.6%
Future return on equity5.3%
Analyst coverage

Low

Last updated25 Oct 2024

Recent future growth updates

Recent updates

Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?

Jan 01
Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?

Revenues Not Telling The Story For Porton Pharma Solutions Ltd. (SZSE:300363) After Shares Rise 31%

Nov 14
Revenues Not Telling The Story For Porton Pharma Solutions Ltd. (SZSE:300363) After Shares Rise 31%

Porton Pharma Solutions Ltd.'s (SZSE:300363) 39% Price Boost Is Out Of Tune With Revenues

Sep 30
Porton Pharma Solutions Ltd.'s (SZSE:300363) 39% Price Boost Is Out Of Tune With Revenues

Porton Pharma Solutions (SZSE:300363) Has Debt But No Earnings; Should You Worry?

Sep 25
Porton Pharma Solutions (SZSE:300363) Has Debt But No Earnings; Should You Worry?

Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?

Jun 26
Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?

Analysts Just Shaved Their Porton Pharma Solutions Ltd. (SZSE:300363) Forecasts Dramatically

May 02
Analysts Just Shaved Their Porton Pharma Solutions Ltd. (SZSE:300363) Forecasts Dramatically

Does Porton Pharma Solutions (SZSE:300363) Have A Healthy Balance Sheet?

Mar 26
Does Porton Pharma Solutions (SZSE:300363) Have A Healthy Balance Sheet?

Porton Pharma Solutions Ltd.'s (SZSE:300363) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Mar 04
Porton Pharma Solutions Ltd.'s (SZSE:300363) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Earnings and Revenue Growth Forecasts

SZSE:300363 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20264,234349N/A8682
12/31/20253,933207N/A5554
12/31/20243,01215N/A6303
9/30/20242,756-391-705-66N/A
6/30/20242,681-314-879-15N/A
3/31/20242,966-122-614355N/A
12/31/20233,667267-501629N/A
9/30/20234,854880-151,199N/A
6/30/20235,4601,2031,7092,876N/A
3/31/20236,9701,9281,3592,593N/A
1/1/20237,0352,0051,3912,564N/A
9/30/20226,2931,7411,3252,533N/A
6/30/20225,7631,522-299850N/A
3/31/20224,005818-103779N/A
1/1/20223,105524-297480N/A
9/30/20212,614446-146415N/A
6/30/20212,40240814487N/A
3/31/20212,224364-46439N/A
12/31/20202,072324110504N/A
9/30/20201,958289177524N/A
6/30/20201,852251189400N/A
3/31/20201,689217240441N/A
12/31/20191,551186176351N/A
9/30/20191,430163148290N/A
6/30/20191,299159182337N/A
3/31/20191,22511940174N/A
12/31/20181,18512425194N/A
9/30/20181,1911346163N/A
6/30/20181,10179N/A-20N/A
3/31/20181,03973N/A170N/A
12/31/20171,184107N/A291N/A
9/30/20171,242121N/A276N/A
6/30/20171,307138N/A458N/A
3/31/20171,399182N/A398N/A
12/31/20161,327171N/A285N/A
9/30/20161,194148N/A183N/A
6/30/20161,097148N/A74N/A
3/31/20161,029125N/A-14N/A
12/31/20151,021110N/A112N/A
9/30/20151,155142N/A349N/A
6/30/20151,156138N/A316N/A
3/31/20151,072127N/A304N/A
12/31/2014987125N/A122N/A
9/30/201471971N/A-90N/A
6/30/201473988N/A-9N/A
3/31/201472390N/A42N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300363 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.8%).

Earnings vs Market: 300363 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 300363 is expected to become profitable in the next 3 years.

Revenue vs Market: 300363's revenue (20.6% per year) is forecast to grow faster than the CN market (13.6% per year).

High Growth Revenue: 300363's revenue (20.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 300363's Return on Equity is forecast to be low in 3 years time (5.3%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 03:08
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Porton Pharma Solutions Ltd. is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jin ZhangChina International Capital Corporation Limited
Feifei XuChina Merchants Securities Co. Ltd.
Zhu ChenCitic Securities Co., Ltd.